There is no set time limit for taking Ozempic. The FDA approved it as a long-term treatment for type 2 diabetes, and the prescribing information includes no maximum duration or stop date. Most people who benefit from the medication stay on it indefinitely, because the conditions it treats (high blood sugar, cardiovascular risk, kidney disease progression) are chronic and tend to return when treatment stops.
Why Ozempic Is Designed for Ongoing Use
Ozempic is FDA-approved for three purposes in adults with type 2 diabetes: improving blood sugar control, reducing the risk of major cardiovascular events like heart attack and stroke, and slowing kidney disease progression. All three are chronic conditions, not problems that resolve after a course of treatment. The prescribing label describes “recommended maintenance dosages” rather than treatment windows, reinforcing that the drug is meant to be continued as long as it’s working and tolerated.
This is similar to how blood pressure or cholesterol medications work. You don’t take them for six months and stop. You take them because the underlying condition persists, and the medication manages it.
What the Long-Term Data Shows
Clinical trials have followed patients on semaglutide (the active ingredient in Ozempic) for multiple years. The FLOW trial, a large international study of over 3,500 people with type 2 diabetes and kidney disease, had a median follow-up of 3.4 years. Participants on semaglutide experienced a 24% reduction in major kidney events, an 18% reduction in major cardiovascular events, and a 20% reduction in the risk of death from any cause compared to placebo.
The SELECT trial, which studied semaglutide in people with obesity and heart disease, also ran for several years and found that serious adverse events were actually less frequent with semaglutide than with placebo. These multi-year studies haven’t revealed safety signals that would justify a time limit on treatment.
What Happens When You Stop
This is the main reason most doctors recommend staying on Ozempic long-term: the benefits reverse when you stop. A 2025 systematic review in The BMJ analyzed weight regain patterns after stopping medications like semaglutide and found that people regained an average of 0.8 kg (about 1.75 pounds) per month after discontinuation. For the newer, more potent medications in the class, total weight regain averaged 9.9 kg (roughly 22 pounds) within the first year off treatment.
Weight isn’t the only thing that bounces back. The same analysis projected that fasting blood sugar, blood pressure, cholesterol, and triglycerides all return to pre-treatment levels within about a year of stopping. HbA1c, the key marker of long-term blood sugar control, was projected to return to baseline within 1.4 years. In practical terms, this means the metabolic improvements you gained while on Ozempic largely disappear once you’re off it.
The Weight Loss Plateau
If you’re taking Ozempic partly for its weight loss effects, you can expect the scale to stop dropping at some point. Clinical data suggests most people hit a weight loss plateau around 60 weeks (roughly 14 months) on semaglutide. This doesn’t mean the drug has stopped working. It means your body has reached a new equilibrium. The medication is still active, still suppressing appetite, and still providing metabolic benefits. The plateau simply reflects the point where your lower body weight requires fewer calories, and intake and expenditure balance out again.
Reaching a plateau is not a reason to stop the medication. Discontinuing at this point typically leads to weight regain and worsening blood sugar control.
Dose Adjustments Over Time
Ozempic starts at a low dose of 0.25 mg weekly for the first four weeks. This initial dose isn’t therapeutic; it’s designed to let your body adjust and reduce nausea. From there, your dose increases to 0.5 mg, then potentially to 1 mg or 2 mg depending on your blood sugar response. The maximum recommended dose is 2 mg once weekly.
Once you reach a maintenance dose that controls your blood sugar effectively, that dose typically stays the same going forward. Some people do well on 0.5 mg long-term, while others need the full 2 mg. For people with type 2 diabetes and chronic kidney disease specifically, the recommended maintenance dose is 1 mg weekly. Your doctor may adjust the dose over time if your blood sugar control changes, but there’s no built-in schedule for tapering off.
Insurance Renewals and Coverage Gaps
Even though there’s no medical time limit, your insurance plan may impose its own timeline. Many insurers require prior authorization for Ozempic, and that authorization expires periodically, often every 6 or 12 months. When it’s time to renew, your insurer will typically want documentation that you’ve had a positive clinical response to the medication, such as improved blood sugar numbers or maintained weight loss.
If your numbers have improved (which they should have, since that’s what the drug does), renewal is generally straightforward. But it does require your doctor’s office to submit paperwork, and gaps in coverage can happen if the process is delayed. Keeping regular appointments and lab work up to date makes this smoother, because your doctor needs recent results to submit with the reauthorization request.
The Thyroid Cancer Concern
One long-term safety question that comes up frequently involves thyroid cancer. Early animal studies found that GLP-1 receptor agonists like semaglutide increased rates of a specific type of thyroid cancer (medullary thyroid carcinoma) in rodents, which led the FDA to add a warning against using these drugs in people with a personal or family history of that cancer or a related genetic condition called MEN2.
In humans, the picture looks different. A recent analysis reviewed by Mayo Clinic researchers concluded that the apparent link between GLP-1 medications and thyroid cancer in human studies likely reflects detection bias, not actual causation. People taking these medications see their doctors more often, get more tests, and are more likely to have incidental thyroid nodules discovered. The current medical consensus does not support routine thyroid cancer screening just because you’re on a GLP-1 medication. If a thyroid nodule is found, it should be evaluated the same way it would be in anyone else.
When Stopping Might Make Sense
There are situations where discontinuing Ozempic is reasonable. Persistent side effects that don’t improve with dose adjustments, a significant change in kidney function, or pregnancy planning are all valid reasons. Some people with type 2 diabetes who make substantial lifestyle changes, such as significant sustained weight loss through diet and exercise or after bariatric surgery, may find their blood sugar stays controlled without medication. But this is the exception, and it requires close monitoring to confirm the condition is truly in remission rather than just masked by recent changes.
For most people with type 2 diabetes, Ozempic is a medication you plan to take for years, potentially for life. The clinical evidence supports this approach, and the consequences of stopping, including weight regain and worsening metabolic markers within months, reinforce why ongoing treatment is the standard recommendation.